Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010
Compared to recombinant human IL-12, SON-1010 demonstrated an enhanced pharmacokinetic (PK) profile that was similar to IgG antibodies SON-1010 continues...